Enamine's IDD Platform Accelerates Nuclide Therapeutics' Precision Radiotheranostics Pipeline Towards the Clinic

Nuclide Therapeutics Leverages Enamine's Deep Expertise in Rapid and Scalable Synthesis of Small Molecules

KYIV, UKRAINE, April 2, 2026 /EINPresswire.com/ -- Nuclide Therapeutics and Enamine initiated their cooperation in 2025. Since then, Enamine has supported Nuclide Therapeutics in progressing from preclinical evaluation towards IND-enabling studies and first-in-human clinical trials for its lead program focused on first-in-class molecular radiotherapies for therapy-resistant cancers. The relationship proved to be highly productive and innovative, delivering development milestones ahead of schedule with short development cycles and efficient use of resources.

Nuclide Therapeutics is committed to advancing a new generation of precision radiotheranostics specifically designed to overcome resistance to current cancer therapies. The collaboration between the two companies has enabled to accelerate key aspects of Nuclide Therapeutics’ preclinical development through Enamine`s strong expertise in synthetic chemistry. Enamine`s ability to deliver high-quality materials within compressed timelines has been instrumental in supporting Nuclide Therapeutics' radiochemistry activities and progressing their program towards IND-enabling studies and first-in-human evaluation.

Enamine’s deep understanding of chemical space is reflected in its REAL Space, the world’s largest and most trusted collection of make-on-demand small molecules, capturing a significant share of synthetically accessible chemical space. REAL Compounds are readily synthesised through validated parallel synthesis protocols using qualified in stock building blocks.

In combination with its integrated capabilities in medicinal chemistry, synthetic chemistry, route scouting, and scale-up, alongside optimized R&D logistics, Enamine enables rapid design-make-test-analyse (DMTA) cycles and efficient production of small molecules within short timelines. Enamine Germany, based in Frankfurt, provides strong support in project coordination, rapid development, and scale-up activities.

𝐑𝐢𝐜𝐡𝐚𝐫𝐝 𝐄𝐝𝐰𝐚𝐫𝐝𝐬, 𝐂𝐨-𝐅𝐨𝐮𝐧𝐝𝐞𝐫 & 𝐂𝐓𝐎 𝐨𝐟 𝐍𝐮𝐜𝐥𝐢𝐝𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬: "𝘖𝘶𝘳 𝘦𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦 𝘸𝘰𝘳𝘬𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘌𝘯𝘢𝘮𝘪𝘯𝘦 𝘩𝘢𝘴 𝘣𝘦𝘦𝘯 𝘦𝘹𝘵𝘳𝘦𝘮𝘦𝘭𝘺 𝘱𝘰𝘴𝘪𝘵𝘪𝘷𝘦. 𝘛𝘩𝘦𝘪𝘳 𝘴𝘵𝘳𝘦𝘯𝘨𝘵𝘩 𝘪𝘯 𝘴𝘺𝘯𝘵𝘩𝘦𝘵𝘪𝘤 𝘤𝘩𝘦𝘮𝘪𝘴𝘵𝘳𝘺, 𝘳𝘰𝘶𝘵𝘦 𝘴𝘤𝘰𝘶𝘵𝘪𝘯𝘨, 𝘢𝘯𝘥 𝘦𝘧𝘧𝘪𝘤𝘪𝘦𝘯𝘵 𝘴𝘤𝘢𝘭𝘦-𝘶𝘱 𝘩𝘢𝘴 𝘢𝘭𝘭𝘰𝘸𝘦𝘥 𝘶𝘴 𝘵𝘰 𝘳𝘢𝘱𝘪𝘥𝘭𝘺 𝘢𝘤𝘤𝘦𝘴𝘴 𝘤𝘳𝘪𝘵𝘪𝘤𝘢𝘭 𝘱𝘳𝘦𝘤𝘶𝘳𝘴𝘰𝘳𝘴 𝘢𝘯𝘥 𝘧𝘪𝘯𝘢𝘭 𝘤𝘰𝘮𝘱𝘰𝘶𝘯𝘥𝘴 𝘢𝘵 𝘵𝘩𝘦 𝘲𝘶𝘢𝘭𝘪𝘵𝘺 𝘢𝘯𝘥 𝘲𝘶𝘢𝘯𝘵𝘪𝘵𝘪𝘦𝘴 𝘳𝘦𝘲𝘶𝘪𝘳𝘦𝘥 𝘧𝘰𝘳 𝘰𝘶𝘳 𝘱𝘳𝘰𝘨𝘳𝘢𝘮. 𝘛𝘩𝘦 𝘵𝘦𝘢𝘮 𝘩𝘢𝘴 𝘤𝘰𝘯𝘴𝘪𝘴𝘵𝘦𝘯𝘵𝘭𝘺 𝘥𝘦𝘭𝘪𝘷𝘦𝘳𝘦𝘥 𝘶𝘯𝘥𝘦𝘳 𝘵𝘪𝘨𝘩𝘵 𝘵𝘪𝘮𝘦𝘭𝘪𝘯𝘦𝘴, 𝘸𝘪𝘵𝘩 𝘦𝘹𝘤𝘦𝘭𝘭𝘦𝘯𝘵 𝘱𝘳𝘰𝘫𝘦𝘤𝘵 𝘮𝘢𝘯𝘢𝘨𝘦𝘮𝘦𝘯𝘵 𝘢𝘯𝘥 𝘤𝘭𝘦𝘢𝘳 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘤𝘢𝘵𝘪𝘰𝘯 𝘵𝘩𝘳𝘰𝘶𝘨𝘩𝘰𝘶𝘵. 𝘌𝘯𝘢𝘮𝘪𝘯𝘦 𝘩𝘢𝘴 𝘣𝘦𝘦𝘯 𝘢 𝘩𝘪𝘨𝘩𝘭𝘺 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘪𝘷𝘦 𝘢𝘯𝘥 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘷𝘦 𝘱𝘢𝘳𝘵𝘯𝘦𝘳, 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘢𝘥𝘥𝘦𝘥 𝘣𝘦𝘯𝘦𝘧𝘪𝘵 𝘰𝘧 𝘤𝘭𝘰𝘴𝘦 𝘪𝘯𝘵𝘦𝘳𝘢𝘤𝘵𝘪𝘰𝘯 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦𝘪𝘳 𝘵𝘦𝘢𝘮𝘴 𝘪𝘯 𝘒𝘺𝘪𝘷 𝘢𝘯𝘥 𝘍𝘳𝘢𝘯𝘬𝘧𝘶𝘳𝘵. 𝘖𝘷𝘦𝘳𝘢𝘭𝘭, 𝘵𝘩𝘦 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘪𝘷𝘪𝘵𝘺, 𝘳𝘦𝘭𝘪𝘢𝘣𝘪𝘭𝘪𝘵𝘺, 𝘢𝘯𝘥 𝘲𝘶𝘢𝘭𝘪𝘵𝘺 𝘰𝘧 𝘰𝘶𝘵𝘱𝘶𝘵 𝘩𝘢𝘷𝘦 𝘣𝘦𝘦𝘯 𝘰𝘶𝘵𝘴𝘵𝘢𝘯𝘥𝘪𝘯𝘨."

𝐒𝐯𝐞𝐧 𝐖𝐚𝐠𝐧𝐞𝐫, 𝐏𝐡𝐃, 𝐕𝐢𝐜𝐞 𝐏𝐫𝐞𝐬𝐢𝐝𝐞𝐧𝐭 𝐨𝐟 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 𝐚𝐭 𝐄𝐧𝐚𝐦𝐢𝐧𝐞: "𝘞𝘦 𝘢𝘳𝘦 𝘷𝘦𝘳𝘺 𝘨𝘭𝘢𝘥 𝘵𝘩𝘢𝘵 𝘌𝘯𝘢𝘮𝘪𝘯𝘦 𝘩𝘢𝘴 𝘵𝘩𝘦 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘺, 𝘸𝘪𝘵𝘩 𝘪𝘵𝘴 𝘬𝘯𝘰𝘸-𝘩𝘰𝘸 𝘢𝘯𝘥 𝘦𝘹𝘦𝘤𝘶𝘵𝘪𝘰𝘯, 𝘵𝘰 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘕𝘶𝘤𝘭𝘪𝘥𝘦 𝘛𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤𝘴, 𝘮𝘦𝘢𝘯𝘪𝘯𝘨𝘧𝘶𝘭 𝘢𝘯𝘥 𝘸𝘪𝘵𝘩𝘰𝘶𝘵 𝘥𝘦𝘭𝘢𝘺, 𝘪𝘯 𝘵𝘩𝘦 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘮𝘦𝘯𝘵 𝘰𝘧 𝘵𝘩𝘦𝘪𝘳 𝘱𝘪𝘰𝘯𝘦𝘦𝘳𝘪𝘯𝘨 𝘳𝘢𝘥𝘪𝘰𝘵𝘩𝘦𝘳𝘢𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘨𝘳𝘢𝘮 𝘵𝘰𝘸𝘢𝘳𝘥𝘴 𝘧𝘪𝘳𝘴𝘵-𝘪𝘯-𝘩𝘶𝘮𝘢𝘯 𝘴𝘵𝘶𝘥𝘪𝘦𝘴 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘰𝘧 𝘳𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘵𝘶𝘮𝘰𝘶𝘳𝘴 𝘸𝘩𝘦𝘳𝘦 𝘦𝘹𝘪𝘴𝘵𝘪𝘯𝘨 𝘤𝘢𝘯𝘤𝘦𝘳 𝘵𝘩𝘦𝘳𝘢𝘱𝘪𝘦𝘴 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘯𝘰 𝘮𝘦𝘥𝘪𝘤𝘢𝘵𝘪𝘰𝘯. 𝘛𝘰𝘨𝘦𝘵𝘩𝘦𝘳, 𝘸𝘦 𝘩𝘢𝘷𝘦 𝘥𝘦𝘮𝘰𝘯𝘴𝘵𝘳𝘢𝘵𝘦𝘥 𝘢𝘯 𝘦𝘹𝘤𝘦𝘱𝘵𝘪𝘰𝘯𝘢𝘭𝘭𝘺 𝘤𝘰𝘰𝘱𝘦𝘳𝘢𝘵𝘪𝘷𝘦 𝘢𝘯𝘥 𝘢𝘨𝘪𝘭𝘦 𝘵𝘦𝘢𝘮 𝘰𝘧 𝘦𝘹𝘱𝘦𝘳𝘵𝘴 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 𝘩𝘪𝘨𝘩𝘭𝘺 𝘱𝘢𝘵𝘪𝘦𝘯𝘵-𝘤𝘦𝘯𝘵𝘳𝘪𝘤 𝘧𝘰𝘤𝘶𝘴 𝘰𝘧 𝘕𝘶𝘤𝘭𝘪𝘥𝘦 𝘛𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤𝘴. 𝘛𝘩𝘪𝘴 𝘴𝘶𝘤𝘤𝘦𝘴𝘴𝘧𝘶𝘭 𝘤𝘰𝘰𝘱𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘦𝘹𝘦𝘮𝘱𝘭𝘪𝘧𝘪𝘦𝘴 𝘵𝘩𝘢𝘵 𝘌𝘯𝘢𝘮𝘪𝘯𝘦 𝘢𝘤𝘤𝘦𝘭𝘦𝘳𝘢𝘵𝘦𝘴 𝘵𝘩𝘦 𝘵𝘳𝘢𝘯𝘴𝘪𝘵𝘪𝘰𝘯 𝘰𝘧 𝘴𝘮𝘢𝘭𝘭 𝘮𝘰𝘭𝘦𝘤𝘶𝘭𝘦 𝘤𝘢𝘯𝘥𝘪𝘥𝘢𝘵𝘦𝘴 𝘪𝘯 𝘱𝘳𝘦𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘸𝘪𝘵𝘩 𝘳𝘢𝘱𝘪𝘥 𝘳𝘰𝘶𝘵𝘦 𝘴𝘤𝘰𝘶𝘵𝘪𝘯𝘨 𝘢𝘯𝘥 𝘶𝘱𝘴𝘤𝘢𝘭𝘪𝘯𝘨 𝘢𝘵 𝘥𝘦𝘴𝘪𝘳𝘦𝘥 𝘴𝘱𝘦𝘤𝘪𝘧𝘪𝘤𝘢𝘵𝘪𝘰𝘯𝘴."

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐒𝐮𝐦𝐦𝐚𝐫𝐢𝐞𝐬:

𝘼𝙗𝙤𝙪𝙩 𝙉𝙪𝙘𝙡𝙞𝙙𝙚 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙇𝙩𝙙.
Nuclide Therapeutics Ltd. is a pioneering clinical-stage biotech company and King’s College London spin-out focused on developing targeted radiopharmaceuticals for therapy-resistant cancers.

For more information, please visit: www.nuclidetx.com

𝘼𝙗𝙤𝙪𝙩 𝙀𝙣𝙖𝙢𝙞𝙣𝙚
Enamine is the leading provider of chemical compounds and a scientifically driven, integrated discovery Contract Research Organisation for integrated drug discovery (IDD) with unique partnering opportunities in exploring new chemical spaces. The company combines access to the in-house produced screening compounds (4.7 million in stock) and building blocks (350,000 in stock) with a comprehensive platform of integrated discovery services in bioinformatics, biology, and chemistry to advance and accelerate the efforts in drug discovery.

For more information, please visit: https://enamine.net

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧

𝙁𝙤𝙧 𝙉𝙪𝙘𝙡𝙞𝙙𝙚 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨:
Richard Edwards, PhD
Co-Founder & CTO
Email: rsedwards@nuclidetx.com

𝙁𝙤𝙧 𝙀𝙣𝙖𝙢𝙞𝙣𝙚:
Oleksii Gavrylenko
Director of Marketing
Email: o.gavrylenko@enamine.net

Oleksii Gavrylenko
Enamine Ltd
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.